This article provides an updated overview of the plethora of complex I inhibitors. The inhibitors are presented within the broad categories of natural and commercial compounds and their potency is related to that of rotenone, the classical inhibitor of complex I. Among commercial products, particular attention is dedicated to inhibitors of pharmacological or toxicological relevance. The compounds that inhibit the NADH-ubiquinone reductase activity of complex I are classified according to three fundamental types of action on the basis of available evidence and recent insights: type A are antagonists of the ubiquinone substrate, type B displace the ubisemiquinone intermediate, and type C are antagonists of the ubiquinol product. q 1998 Elsevier Science B.V.
Introduction

Ž
. NADH-ubiquinone reductase EC 1.5.6.3 is the energy-conserving enzyme complex that is comw x monly known as complex I 1-3 . Complex I embodies the first phosphorylation site of mitochondria and Abbreviations: CCCP, carbonyl cyanide-m-chlorophenylhydrazone; DB, decyl-Q analogue; DCCD, docyclohexylcarbodiimide; DCIP, dichlorophenolindophenol; DNP, 2,4-dinitrophenol; DPI, diphenyleneiodonium; DQ, duroquinone; I , inhibitor con-50 q Ž . centration producing 50% inhibition; HPP , 4-4-chlorophenyl -Ž . 1-4-4-fluorophenyl -4-oxobutyl-pyridinium; MOA, methoxyacrylate; MPP q , 1-methyl-4-phenyl-pyridinium; MPTP, 1methyl-4-phenyl-1,2,3,4,-tetrahydropyridine; 2M-TIO, 2-methyl-Ž . w x 6-2-thienyl imidazo 2,1-b thiazole; NP, 4-nonylphenol; Q, ubiquinone; Q-1, Q-2, ubiquinone-1, -2; QH , ubiquinol; RET, 2 reverse electron transfer to NAD q ; SAN, Sandoz quinazoline compounds; SMP, submitochondrial particles; TDS, tridecyl stigmatellin; TIQ, tetrahydroisoquinoline; UBQ, undecyl-Q analogue ) Corresponding author. Fax: q61-3-99054699; E-mail: mauro.esposti@med.monash.edu.au is first among the respiratory complexes also in the number of inhibitors. Over sixty different families of compounds are known to inhibit complex I, but recent articles have considered only a fraction of w x these 4-8 , while the reviews on complex I inw x hibitors are becoming dated 9,10 . The purpose of this article is to provide an overview of the plethora of complex I inhibitors. To concisely present a large body of information, I introduce first a broad distinction among compounds of natural and commercial origin, and then propose a new functional classifica-Ž . tion of complex I inhibitors based on ubiquinone Q reaction sites.
The plethora of complex I inhibitors
The number of compounds that inhibit complex I is ever increasing, and it is impossible to classify them in chemical terms. Tables 1 and 2 report the ( ) diverse inhibitors divided into natural and commercial products with potency related to that of rotenone, w x the classical inhibitor of complex I 4,9,10 . The relative potency of natural inhibitors is often expressed in terms of the ratio with the K of rotenone I Ž . Table 1 , that is 4 nM in our standard assay of w x w x NADH-Q reductase 8 . See Refs. 4,56 for a review on compounds that inhibit complex I among other enzymes, e.g. sulphydryl reagents.
Characteristics of complex I inhibition
A few compounds inhibit NADH interaction, but are not specific for complex I since they also affect Ž w x. other dehydrogenases e.g. rhein 9,10,23 . Therefore, the great majority of complex I inhibitors act on the NADH-Q reductase activity, which is the limitw x ing reaction in NADH oxidation 4,57,58 , without inhibiting the NADH-ferricyanide reductase activity w x 4,9,59,13 . The inhibition of complex I can be measured in different ways. In coupled submitochondrial particles it is possible to follow the energy-dependent Ž . q w x reverse electron transfer RET to NAD 60 [77] [78] [79] suggests that complex I activity is delicate also in transformed cells, probably because they usually have a smaller number of mitochondria than their parent normal cells.
Complex I inhibitors of natural origin
In essence, the structure of potent natural inhibitors of complex I has a modular similarity with ubiquinone, with a cyclic 'head' corresponding to the ubiquinone ring and a hydrophobic 'tail'. Natural variations within each family of inhibitors is normally restricted to substitutions and degrees of oxy-Ž genation of the tail see also the contribution of w x. Miyoshi 80 .
Rotenoids
Rotenone is the most potent member of the rotenoids, a family of isoflavonoids extracted from w x Leguminosae plants 12,70,81 , and since the early w x reports 69,81 has become the classical inhibitor of w x complex I 1,4,10,56,68 . Rotenone inhibition is w x markedly time-dependent 4,9,12 , which easily leads to under-estimations of its potency-a K as low as x with C rotenone have indicated a specific binding titre of 0.06-0.07 nmolrmg protein in beef heart w x SMP 82 and I values approach this titre when the 50 particle concentration is above 0.1 mgrml in the assay. Binding studies by Singer and coworkers have indicated that amytal, piericidin A and 1-methyl-4-Ž q . phenyl-pyridinium MPP displace rotenone from w x its specific site in complex I 4,9,56,82 . Results with w x w x photoaffinity labelling 83 , fluorescent dyes 84 and w 3 x w x H dihydrorotenone 6,85 have later clarified that rotenone does not compete with Q analogues. Photoaffinity labelling data have suggested that the ND1 subunit could be directly involved in forming the w x rotenone binding site 86,87 . Investigations on human disease mutations partly sustain this possibility and indicate that also the ND4 subunit could be w x involved in rotenone binding 88,89 .
Piericidins
Piericidins are 2,3-dimethoxy-4-hydroxy-5-methy-6-polyprenyl-pyridine antibiotics produced by some w x Streptomyces strains 90 that have contributed extensively to the definition of the enzyme properties of w x complex I 4,9-11,13,14,56,91-94 . The methylation of the hydroxyl group at position 10 of the tail in natural piericidin B and D seems to reduce potency w x 11,93 , consistent with the diminished potency of the 6-isoprenyl derivatives of piericidins, usually called w x ubicidins 14,92 . The close similarity with ubiquinone renders piericidin A an effective inhibitor Ž w x of several Q-reacting enzymes see Ref. 16 and . reference therein . Complex I, however, remains the most specific site of piericidin inhibition, with a K I w x w x ranging between 0.6 14,91 and 1 nM 8 . Studies w 14 x with C piericidin A have indicated that complex I has two binding sites for the inhibitor in the native w x membrane 13,94 , one of which inhibits energy-de-w x pendent RET more potently than NADH oxidase 94 . The tight binding of piericidin A to complex I essentially prevents its displacement by rotenone and amyw x tal 4,9,11 . However, a partial displacement of bound piericidin A has been obtained with certain analogues q w x of MPP 4,95 , whilst the acetogenin rolliniastatin-2 w x is mutually exclusive with piericidin A 8 . New information on the molecular interaction of piericidin will be hopefully obtained with the resistant mutants w x recently described in Rhodobacter 71 . Various hydroxyl groups are distributed along the molecule and seem to be essential for inhibition w x 5,77,96 . However, little information is available on the structure-activity of these inhibitors, in part due to the limited natural variations that are confined to the number of hydroxyl groups and the structure or stereochemistry of the tetrahydrofuran nucleus w x 77,79,96 . This tetrahydrofuran nucleus is likely to be fundamental for biological activity, since it could Ž w x. mimic the quinoid head of ubiquinone cf. Ref. 5 . The part of the molecule with the lactone could correspond to the hydrophobic tail of other inhibitors such as piericidins, whereas the aliphatic part could essentially act as a lipophilic anchor. Table 1 : a Potency relative to that of rotenone measured under the same conditions in beef mitochondria or submitochondrial particles. The relative potency is measured using the ratio of the K values, when they are available. NADH-Q reductase is with hydrophobic Q analogues such I as DB, UBQ and Q-2. b These inhibitors are general Q antagonists since they inhibit also other Q-reacting enzymes, especially cytochrome bc complex and 1 bacterial reaction centres. c Rhein specifically inhibits the rotenone-insensitive reduction of ferricyanide and acts as a NADH antagonist in soluble mitochondrial w x NADH dehydrogenase, as well as in other dehydrogenases 9,23 . Table 1 reports other antibiotic inhibitors such as ÄŽ . w aureothin Z, E -2-methoxy-3,5-dimethyl-6-tetrahyw Ž .
Annonaceous acetogenins
Notes to
Other antibiotics
x dro-4-2-methyl-3-4-nitrophenyl -2-propenylidene -2-
x 4 w x furanyl -4h-pyran-4-one 106 which seems to act w x like rotenone 7 . Among cochlioquinones, a family of fungal toxins of polycyclic structure, cochlioquinone B seems to be specific for the NADH-Q w x reductase activity 18 . x . malian SMP 7,21,22,31 , but shows the rare property of competitive inhibition vs. Q substrates in w x isolated complex I 20 . In SMP, the kinetic behaviour of capsaicin is biphasic or mixed-competitive Ž w x. as for several other inhibitors cf. Refs. 21,22 . Table 1 lists other plant products that do not belong to families of specific inhibitors of complex I such as w x papaverine, a compound present in opium 24 .
Vanilloids and other plant products
ÄŽ . wŽ . Capsaicin E -n-4-hydroxy-3-methoxyphenyl - x 4 methyl -8-methyl-6-
Ubiquinones
Short-chain quinones such as Q-2, Q-3 and octyl-Q function both as substrates and inhibitors of NADH w x oxidation in mammalian mitochondria 25-28,67 . These quinone analogues accept electrons from comw x plex I and become inhibitory once reduced 25,27 , a Notes to Table 2 : a Ž I minimal in beef or rat mitochondrial preparations with the assay system indicated NADH:O represents both NADH oxidase 50 2 . determined spectrophotometrically and site one respiration determined with the oxygen electrode . Due to the abundance of data, the major reference assay is NADH-Q-1 reductase. b Relative to the I of rotenone assayed under the same conditions. 50 c DPI inhibits also the oxidation of NADH by either ferricyanide or DCIP in the absence of exogenous Q analogues, especially in purified w x complex I 55 .
( ) suicide-like action that seems to derive from semiquinone instability, since it increases oxygen w x radical production in complex I 25,28 . The hydroxydecyl Q analogue idebenone is more potent than w x Q-2 and specifically inhibits membrane potential 28 , which raises some worries for its use as a nootropic w x drug 109 .
Synthetic and commercial inhibitors
Pesticides and agrochemicals
A new series of pesticides inhibiting complex I has w x been developed in the last few years 5,6 and now commercialized as acaricides. SAN547A and w x SAN548A 5 are N-alkyl-4-aminoquinazolines rew x lated to the pesticide fenazaquin 110-112 and probably constitute the most potent synthetic inhibitors of Ž . Ä complex I 
2-tert-butyl-5-4-tert-butylbenzylthio -4-chloro-
Ž . 4 pyridazin-3 2 h -one is a pyrazole acaricide that seems to be superior to rotenone as inhibitor of w xŽ . mammalian complex I 5,114 Table 2 . Pyridaben is w x also more potent than tebufenpyrad 115 Ä Ž . n-4-tert-butylbenzyl -4-chloro-3-ethyl-1-methyl-5-4 Ž . pyrazolecarboxamide Table 2 that is commercialw x ized with the tradename pyranica 116,117 .
Among benzimidazole compounds with insectici-Ž dal properties, 1-3,7-dimethyl-7-isobutyloxy-2-oc-
. w x tenyl -2-methylbenzimidazole 118 seems to be more potent than rotenone in mammalian mitochondria Ž w x . 
Drugs and toxins
Whereas complex I is the target for new pesticides in agrochemistry, complex I inhibition is an increasing toxicological problem, since it constitutes an undesired side-effect of several drugs used in medicine. Indeed, many pharmacologically important compounds inhibit NADH-Q reductase and their potency in isolated mitochondria, albeit weak when Ž . compared with acaricide inhibitors Table 2 , is not w directly proportional to the pathological effects 34x 37,122 .
Tranquillizers
Ž The tranquillizer barbiturate amytal 5-ethyl-5-iso-. amylbarbituric acid is the oldest established inhibitor w x Ä of complex I 4,9,10,32 . Meperidine 1-methyl-4-4 phenyl-4-piperidinecarboxylic acid ethyl ester , also called pethidine or demerol, is another analgesic drug w x known to inhibit complex I 33,63 . Werner and coworkers have synthetized hydrophobic analogues which are about 100-fold more potent than pethidine w x in inhibiting NADH-Q reductase 33 and a radioactive analogue which apparently is not displaced by w x rotenone 123 . This agrees with enzymatic data showing that meperidine or demerol is non-exclusive w x with rotenoids and other inhibitors of complex I 17 .
Neurotoxins
The neurotoxin 1-methyl-4-phenyl-1,2,3,4,-tetra-Ž . hydropyridine MPTP induces parkinsonism in humans once transformed into the pyridinium metabolite MPP q , which is responsible for the specific w x q toxicity in dopaminergic neurons 34, 35, 122 . MPP is a rather weak inhibitor in broken mitochondria or SMP, but in coupled mitochondria is actively accumulated in the matrix due to its positive charge, with w x a dramatic increase in potency [34] [35] [36] 122 . Some 4 X -alkyl analogues of MPP q are inhibitory in the w x micromolar range 36,37 and displace either rotenone or piericidin A from its binding site in complex I w x 4,95,124,125 , but seem to have two distinct interacw x tion sites 36,37,95 . Extensive research has been undertaken to find compounds with an action similar ( ) to that of MPP q and hopefully rationalize the spontaneous occurrence of Parkinson's disease. Potential candidates include indole-derived-b-carboline comw x pounds such as harmane 38 , the antiseptic dequalinw x w x ium 43 , laser dyes 35 and the naturally-occurring w x aminoethylcysteine ketimine dimer 39 and tetrahy-Ž . w x dro-isoquinoline TIQ 24,126,40 . Finally, dopamine and other catecholamine neurotransmitters have well w x known neurotoxic effects 127 that are possibly corw x related to complex I inhibition 24, 127, 128 . This correlation, however, is not proven yet.
Neuroleptic drugs
Anti-psychotic or neuroleptic drugs have long been suspected to interfere with mitochondrial function w
x 129,130 . The common side-effects of neuroleptic w x treatment include parkinsonism 131 , which has been recently correlated to complex I inhibition in isolated w x mitochondria 41 . Further correlations between the side-effects of neuroleptic medication and parkinsonism derive from the discovery of pyridinium metabo-Ä X Ž lites of the drug haloperidol 4 -fluoro-4-4-hydroxy-. 4 4-p-chorophenylpiperidino butyrophenone in paw x q tients 132,133 . These metabolites resemble MPP not only in structure, but also in their mode of w x complex I inhibition 42 .
Piperazine drugs
Recently, some commercial drugs derived from Ž . piperazine diethylenediamine have been found to Ž inhibit complex I in the micromolar range Table 2 , w
x. c f. R e fs. 4 4 ,4 5 . T h e y in c lu d e th e w x anticonvulsantrantihistaminic cinnarizine 44 and the Ä w Ž . antianginal ranolazine 1-3-2-methoxyphenoxy -2-
x w Ž . hydroxypropyl -4-N-2,6-dimethylphenyl carbamoylx 4 w x methyl piperazine 45 . Ranolazine has some unusual features as complex I inhibitor, since it displays an w x uncompetitive behaviour with respect to Q-1 45 w x similarly to annonaceous acetogenins 8 .
Phenolic chemicals
Besides catechol, several other phenolic com-Ž . pounds inhibit complex I. 4-nonylphenol NP , a pollutant derived from non-ionic detergents, is more Ž . potent than 2,4-dinitrophenol DNP and other uncouplers such as carbonyl cyanide-m-chlorophenylhy-Ž . Ž . drazone CCCP Table 2 . NP appears to compete with quinol product inhibitors in complex I and is mutually exclusive with stigmatellins and myxothia-Ž . zol A. Ghelli, M. Degli Esposti, unpublished data . A series of 2-alkyl-dinitrophenols has been developed as general Q antagonist inhibitors, but their inhibition w x of complex I is only partial 47 . Related to nitrophe-Ä Ž . Ž n o ls is V a c o r 1 -4 -n itro p h e n y l -3 -3 -.
4 pyridylmethyl urea , a rat poison that induces an acute condition of insulin-dependent diabetes in huw x mans 134 . Complex I inhibition is responsible for w x the diabetogenic action of Vacor 46 .
Quinone antagonists
Oettmeier and coworkers have synthesized new w x quinone-related inhibitors 48,49,135 . Acridones with a 4-alkyl tail of eight carbons display maximal potency for complex I, which is about one-order of w x magnitude lower than that of rotenone 48,135 . Binding studies have shown an apparent displacement of w x acridones by rotenone 6,135 . The 2-n-undecyl-3methyl analogue is the most potent of the quinolone series, even more than its related aurachins in both w x complex I and cytochrome bc complexes 49 . The 1 acridone and quinolone inhibitors presumably act as Q antagonists in complex I, but they do not behave w x competitively with Q-1 48 .
Fluorescent dyes
Acridones are closely related to acridines and fluoresceins, which include many fluorescent dyes used in biological studies. The mitochondrial toxicity of potential-sensitive dyes such as carbocyanines has w x long been known 136 and essentially derives from complex I inhibition, as established in extensive studw x ies 50,137-139 . Erythrosine iodoacetamide, a fluorescein derivative, probably is the most potent dye Ž w x. inhibiting complex I Table 2 , cf. Refs. 50,84 ; its binding to isolated complex I is mutually exclusive w x with DB but not with rotenone 84 . It is noteworthy w x that among oxonol dyes, including tinopal 72 , only oxonol-VI does not inhibit complex I.
Group reagents
The classical carboxyl reagent dicyclohexyl-carbo-Ž . w x diimide DCCD 53 and the metal chelator o- ( ) phenanthroline have been found to inhibit complex I, w x as well as other membrane systems 54,140 . Con-Ž . versely, the flavin reagent diphenyleneiodonium DPI w x inhibits complex I with high potency 55 . Although originally reported as inhibitor of the NADH-Q rew x ductase activity 52 , DPI covalently attacks the FMN cofactor after reduction of isolated complex I and thus blocks electron transport to hydrophilic accepw x tors such as DCIP 55 .
Functional classification of inhibitors of NADH-Q reductase
In examining the variety of complex I inhibitors it emerges that several compounds seem to act differently from rotenone. Rotenone itself is likely to bind w x to two sites 4,68,94 , as originally indicated by w x binding studies with piericidins 11,13,14,91 . Indeed, concentrations of rotenone that saturate its specific site do not significantly displace bound piericidin A w x 11,13 , which suggests that the binding of the two inhibitors is either independent or overlapping only in part. Moreover, some new inhibitors such as myxothiazol are non exclusive with either rotenone or w x piericidin 17,58 . How can we distinguish functionally different sites for complex I inhibitors?
There is an increasing consensus of opinion that complex I has multiple Q reaction sites, but it is arduous to define a clearcut distinction among these sites. Perhaps most compelling is the theoretical consideration that no less than two Q action sites need to be present in complex I to account for the generally accepted stoichiometry of two protons per electron w x 1-4,58 . A consequence of this minimal requirement is that some inhibitors could interfere with protonmotive reactions differently from other inhibitors depending on their interaction with a given Q site. In fact, one of the two piericidin A sites affects more potently energy-dependent RET than NADH oxida- x tion 13,94 ; most likely, rolliniastatin-2 specifically w x interacts at this site 8,58 . By contrast, rotenone inhibits more effectively NADH oxidation than enw x ergy-dependent RET 8, 68, 141 and is less efficient than rolliniastatin-2 in inhibiting the proton pumping activity of complex I under limited turnover condi-w x tions 58 . Rotenone and piericidin A also differ in their kinetic behaviour towards Q analogue subw strates. Rotenone is consistently non-competitive 6x 8,31,33,22,48,45 , whereas piericidin A is competiw x tive with endogenous Q 91,14,94 and partially comw x petitive with some exogenous Q analogues 7 . Note Fig. 1 . A diagram for the action of the three fundamental types of inhibitors of NADH-Q reductase. The diagram represents the minimal w x steps of Q reduction by complex I and derives from the dual Q-gated pump model 58 modified to account for the likely protonmotive w x role of cluster N2 3 . The first electron from NADH, through oxidoreduction of cluster N2, reduces a firmly bound Q molecule at site B, w x forming a stabilized ubisemiquinone that corresponds to the rotenone-sensitive radical 142-144 , and produces some charge separation w x 51 . The second electron from NADH is transferred by the low-potential cofactors to another molecule of ubiquinone which enters the w x complex at the hydrophobic site A and activates proton pumping 58 . Rolliniastatin-2 and other type A inhibitors antagonize Q at this site. The second semiquinone formed at site A then dismute with the more stable semiquinone at site B, producing the ubiquinol product that leaves the complex. Oxidized Q remains at site B after dismutation to re-initiate the catalytic cycle. The dismutation of the two w x semiquinones is a critical step in the proper function of complex I 143 . With exogenous analogues such as Q-2 that have a pronounced semiquinone instability, the dismutation step can diverge from the normal route, producing quinol at the 'wrong' site, as illustrated by the white arrow and the rightmost enzyme form in the diagram. I hypothesize that type C inhibitors act by effectively enhancing this unproductive form of the enzyme at steady-state. To do so, they could either interact directly with the quinol-releasing site, or interfere with the dismutation reaction of the semiquinones in sites A and B. Presumably, the dismutation reaction of the two semiquinones is also associated with charge separation across the membrane, and its destabilization may enhance the production of oxygen radical species by complex I.
(
) that rolliniastatin-2 shows competitive behaviour with Ž idebenone and decyl-plastoquinone M. Degli Es-. posti, A. Ghelli, unpublished data but uncompetitive w x behaviour with other Q analogues 8 .
By combining these different properties, complex I inhibitors can be broadly classified into inhibitors Ž acting like rolliniastatin-2 or piericidin A at one of . Ž its two sites and inhibitors acting like rotenone at its . most specific site . These two types of inhibitors would partially correspond to class I and II, respecw x tively, that were proposed previously 7 and include several other compounds chemically unrelated to rotenoids or piericidins. However, there are some inhibitors that fit neither the rotenone nor the rolliniastatin-2rpiericidin A type. For instance quinol analogues, especially Q2H , are particularly potent for 2 the membrane potential generation of complex I and the redox activity with hydrophilic substrates such as w x Q-1, that promote inefficient proton pumping 25,67 -presumably because these quinones are protonated in the aqueous phase and not within the membrane like natural ubiquinone. Myxothiazol, stigmatellin, NP, capsaicin, demerol and some cationic MPP q analogues also appear to interact with a hydrophilic w x site in complex I 17,37 and share the inhibitory properties of quinols. Hence, these compounds could form a third type of complex I inhibitors which w x essentially act as the quinol product 58 .
Given the above, I propose a functional classification of various complex I inhibitors into three funda-Ž . mental types Table 3 that interfere with basic steps in Q reduction as schematically illustrated in Fig. 1 . In brief, they act as: A, direct antagonists of Q substrate at the entry of the hydrophobic site in the complex; B, antagonists of the semiquinone intermediate stabilized within the complex; and C, antagonists of either the formation or release of the quinol product. Different chemical determinants are associated with these three types of inhibitors. Type A inhibitors possess a hydroxyl group both in the cyclic head and the hydrophobic tail, optimally spaced by 10-12 carbons as in piericidin A, rolliniastatin-2 and idebenone. Conversely, type B inhibitors have only H-bonding acceptors in the head and no hydroxy groups in the tail. In fact, even piericidins without the hydroxyl group in the tail displace bound rotenone w x but not bound piericidin A 11,14 . By using these w x inferences and earlier data 7 , phenalamid, aurachins and also erythrosin could be classified as type A inhibitors. Type C inhibitors, instead, generally possess a hydroxy or amino group in the head. However, the hydrophilic site at which they are supposed to interact is likely to have a rather weak specificity for recognizing chemically different compounds, and may as well accept substances that bind with more affinity to other sites in complex I, e.g. rotenone.
Two qualifications are required with regard to the Ž . new classification proposed here Table 3 . First, for some inhibitors the classification is essentially based upon inferences that need to be experimentally tested. Secondly, several inhibitors besides rotenone and piericidin A could interact at multiple sites depending on their concentration. Consequently, binding displacement results could over-estimate the extent of mutual overlapping in the specific interaction of certain inhibitors. However, by combining the results of complementary approaches it should be possible to define the most specific action of any inhibitor of complex I according to the three fundamental types outlined in Table 3 . 
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